Familial Dysglobulinemia (PreFamDys)

Civil Hospices of Lyon

Status: Completed

Conditions: Dysglobulinemia

Treatments: Genetic: Genetic analysis of peripheral blood samples

Study type: Interventional

Funder types: Other

Identifiers

NCT02853214

2007-460

2007-A00644-49 (Other Identifier)

Details and patient eligibility

About

Multiple Myeloma (MM) is a malignant proliferation of monoclonal plasma cells. Myeloma accounts for almost 14% of all hematologic cancers and is essentially incurable. Myeloma commonly evolves from a precursor disease, Monoclonal gammopathy of undetermined significance (MGUS). Despite intensive study, the etiology of MGUS and myeloma are unknown and no lifestyle or environmental exposure factors have been identified that are consistently linked to increased risk of MM, MGUS or the transition between the two.

The overall goal is to identify risk genes for dysglobulinemia, and more specifically Multiple Myeloma. This will involve the conservation of cells in a bank and genetic sequencing on samples obtained from families with at least two cases of dysglobulinemia. Material used for sequencing is likely to include fresh peripheral blood cells or lymphoblastoid lines established from peripheral blood lymphocytes of patients.

Enrollment: 1,868 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 2 cases per family at least
• 1 case alive at least
• biological material available for 1 case at least
• Patients give their informed consent
• attached to the French Health protection service

Exclusion criteria

• Age under 18

Trial design

Primary purpose: Screening

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1,868 participants in 1 patient group

Identification of genetic factors in dysglobulinemia cases

Experimental group

Treatment:

Genetic: Genetic analysis of peripheral blood samples